Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
3 findings from 1 review
no estimate extracted
1 study · 77 participants
Very low
no estimate extracted
1 study · 100 participants
Very low
no estimate extracted
1 study · 77 participants
Low
Prevalence of parosmia · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Healing of MRONJ (mucosal integrity) · People with MRONJ referred for surgical treatment
It is very uncertain whether autofluorescence-guided bone surgery changes healing of MRONJ (mucosal integrity) compared with tetracycline fluorescence-guided bone surgery (very low certainty).
1 finding from 1 review
MRONJ after tooth extraction (incidence proportion) · People on antiresorptive treatment undergoing tooth extraction (at risk of MRONJ)
Subperiosteal prepared (SPP) wound closure after tooth extraction showed no clear difference in MRONJ after tooth extraction (incidence proportion) compared with epiperiosteal prepared (EPP) wound closure after tooth extraction (low certainty).
1 finding from 1 review
Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Induction cisplatin+5-FU+docetaxel vs cisplatin+5-FU: disease-free survival HR 0.72 (95% CI 0.57 to 0.91, P = 0.006; Vermorken 2007). Prior to concurrent chemoradiation: Posner 2007 HR 0.71 (0.56 to 0.90, P = 0.005).…
2 studies
GRADE not reported
Overall survival, induction cisplatin + 5-fluorouracil + docetaxel prior to concurrent chemoradiation (cisplatin) vs concurrent chemoradiation (cisplatin) · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… showed no clear difference in overall survival, induction cisplatin + 5-fluorouracil + docetaxel… compared with locoregional treatment (radiotherapy and/or surgery) alone (low certainty).
1 finding from 1 review
Locoregional control · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… led to lower locoregional control, induction cisplatin + 5-fluorouracil +… compared with locoregional treatment (radiotherapy and/or surgery) alone; GRADE not reported.
1 finding from 1 review
RR 0.80 [0.64, 0.99]
3 studies
GRADE not reported
Quality of life · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
The review found no eligible studies for this question.
1 finding from 1 review
Overall survival, induction platinum + 5-fluorouracil prior to surgery vs surgery alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… showed no clear difference in overall survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone (low certainty).
1 finding from 1 review
Failure of therapy · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
It is very uncertain whether selective carious tissue removal (selective excavation, SE) changes failure of therapy compared with hall Technique (sealing with a preformed metal crown) (very low certainty).
2 findings from 1 review